Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27932455 | 0.87 | TP53 (0.51) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL54880 | 0.86 | ALDH1A1 (0.66) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL728757 | 0.86 | ALDH1A1 (0.66) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL410432 | 0.83 | TP53 (0.55) | ALDH1A1CYP3A4SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2301797 | 0.81 | CYP3A4 (0.75) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL15542206 | 0.81 | ALDH1A1 (0.56) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL27257749 | 0.81 | ALOX5 (0.46) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL16958158 | 0.79 | SMN1; SMN2 (0.46) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 | |
| SCHEMBL11689544 | 0.79 | ALDH1A1 (0.58) | ALDH1A1TSHRCYP3A4SMN1; SMN2CES1 | |
| SCHEMBL30917331 | 0.79 | ALDH1A1 (0.58) | ALDH1A1TSHRCYP3A4SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389373-B1 | DERIVATIVES OF N2-(3-PYRIDYL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9149475-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9149475-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| EP-1696920-B1 | COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS | PLEXXIKON INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20130210810-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210810-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8067434-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | PLEXXIKON INC | 2010-12-23 | — | — | US | disclosed |
| WO-2010090875-A1 | DERIVATIVES OF N2-(3-PYRIDIL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
| CN-1925855-B | Compounds and methods for development of Ret modulators | PLEXXIKON INC | 2010-06-16 | — | — | CN | disclosed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | PLEXXIKON, INC. | 2007-03-22 | — | — | US | disclosed |
| CN-1925855-A | Compounds and methods for development of Ret modulators | PLEXXIKON INC (US) | 2007-03-07 | — | — | CN | disclosed |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885TSHR 3710/4885CYP3A4 4316/4885 |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | RET, GFRA3, GFRA1 | ALDH1A1 3687/4885TSHR 73/4885CYP3A4 4802/4885 |
| US-20130210810-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885TSHR 3710/4885CYP3A4 4316/4885 |
| US-20070066641-A1 | Compounds and methods for development of RET modulators | RET, FGFR1, FGFR3 | ALDH1A1 3400/4885TSHR 138/4885CYP3A4 4665/4885 |
| US-20070049615-A1 | Compounds and methods for development of Ret modulators | RET, GFRA1, GFRA3 | ALDH1A1 3491/4885TSHR 69/4885CYP3A4 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.